Idsk -- A double-blind, randomized, placebo-controlled trial of the cholinesterase-inhibiting drug rivastigmine was halted prematurely when it was shown to be ineffective and potentially fatal for critical care patients experiencing delirium, according to a report in the Nov. 5 issue of the Lancet.
